Orchid Chemicals' drug units get UK approval

New Delhi, Sep 21 (UNI) Orchid Chemicals and Pharmaceuticals today said its sterile cephalosporin finished dosage form has received approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).

Orchid plans to launch key cephalosporin products in the European market next year, the company said in a statement.

''We hope to derive major revenues from the European generics thrust based on progressive receipt of marketing authorisations,'' said Orchid MD K Raghavendra Rao.

Orchid's Active Pharmaceutical Ingredients (APIs) facilities located at Irungattukottai and Alathur near Chennai have also been approved by the UK regulator.

These approvals which followed the facility inspections conducted in the respective locations by the Agency validate the quality, regulatory and compliance standards of the company.

These approvals will pave the way for receiving marketing authorisations for various products based on review of product dossiers by the regulatory authority.

UNI PV PDM DB1335